Research Article
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
Figure 2
Levels of serum prooxidants in individuals with type 1 diabetes, before and after treatment with empagliflozin 25 mg daily (EMPA), metformin 2000 mg daily (MET), empagliflozin-metformin combination (EMPA-MET COMB), or in control (CTRL) groups: (a) advanced oxidation protein products (AOPP), (b) isoprostane, and (c) advanced glycation end products (AGE). represents ; represents , and represents .
(a) |
(b) |
(c) |